APO Research
Talk to an analyst

APO RESEARCH · REPORT

Decitabine for Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Decitabine for Injection Market Outlook and Growth Opportunities 2026

29 December 2025190 pages

Choose your research edition.

Industry ResearchDecitabine for Injection Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Decitabine for Injection Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Decitabine for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Decitabine for Injection Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Decitabine for Injection Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Decitabine for Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Decitabine for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Decitabine for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Decitabine for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Decitabine for Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Decitabine for Injection market include Astex Pharmaceuticals, Hansoh Pharmaceutical, Ingenus Pharmaceutical, Meitheal Pharmaceuticals, Otsuka US, Sagent Pharmaceuticals, Huiyu Pharmaceutical, Qilu Pharmaceutical and Xian Janssen Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Decitabine for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Decitabine for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Decitabine for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Decitabine for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Decitabine for Injection Segment by Company

Astex Pharmaceuticals

Hansoh Pharmaceutical

Ingenus Pharmaceutical

Meitheal Pharmaceuticals

Otsuka US

Sagent Pharmaceuticals

Huiyu Pharmaceutical

Qilu Pharmaceutical

Xian Janssen Pharmaceutical

Chia Tai Tianqing Pharmaceutical Group

Decitabine for Injection Segment by Type

50mg/Bottle

Other

Decitabine for Injection Segment by Application

Hospital

Clinic

Decitabine for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Decitabine for Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Decitabine for Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Decitabine for Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Decitabine for Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Decitabine for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Decitabine for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Decitabine for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Decitabine for Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Decitabine for Injection industry.

Chapter 3: Detailed analysis of Decitabine for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Decitabine for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Decitabine for Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Decitabine for Injection Industry Trends Table 2. Decitabine for Injection Industry Drivers Table 3. Decitabine for Injection Industry Opportunities and Challenges Table 4. Decitabine for Injection Industry Restraints Table 5. Global Decitabine for Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Decitabine for Injection Revenue Share by Company (2021-2026) Table 7. Global Decitabine for Injection Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Decitabine for Injection Sales Volume Share by Company (2021-2026) Table 9. Global Decitabine for Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Decitabine for Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Decitabine for Injection Key Company Manufacturing Base & Headquarters Table 12. Global Decitabine for Injection Company, Product Type & Application Table 13. Global Decitabine for Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Decitabine for Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 50mg/Bottle Table 18. Significant Companies of Other Table 19. Global Decitabine for Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Decitabine for Injection Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Decitabine for Injection Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Decitabine for Injection Sales Volume Share by Type (2021-2026) Table 23. Global Decitabine for Injection Sales Volume Share by Type (2027-2032) Table 24. Global Decitabine for Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Decitabine for Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Decitabine for Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Decitabine for Injection Sales Value Share by Type (2021-2026) Table 28. Global Decitabine for Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Decitabine for Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Decitabine for Injection Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Decitabine for Injection Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Decitabine for Injection Sales Volume Share by Application (2021-2026) Table 35. Global Decitabine for Injection Sales Volume Share by Application (2027-2032) Table 36. Global Decitabine for Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Decitabine for Injection Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Decitabine for Injection Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Decitabine for Injection Sales Value Share by Application (2021-2026) Table 40. Global Decitabine for Injection Sales Value Share by Application (2027-2032) Table 41. Global Decitabine for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Decitabine for Injection Sales by Region (2021-2026) & (K Units) Table 43. Global Decitabine for Injection Sales Market Share by Region (2021-2026) Table 44. Global Decitabine for Injection Sales by Region (2027-2032) & (K Units) Table 45. Global Decitabine for Injection Sales Market Share by Region (2027-2032) Table 46. Global Decitabine for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Decitabine for Injection Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Decitabine for Injection Sales Value Share by Region (2021-2026) Table 49. Global Decitabine for Injection Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Decitabine for Injection Sales Value Share by Region (2027-2032) Table 51. Global Decitabine for Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Decitabine for Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Decitabine for Injection Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Decitabine for Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Decitabine for Injection Sales by Country (2021-2026) & (K Units) Table 56. Global Decitabine for Injection Sales Market Share by Country (2021-2026) Table 57. Global Decitabine for Injection Sales by Country (2027-2032) & (K Units) Table 58. Global Decitabine for Injection Sales Market Share by Country (2027-2032) Table 59. Global Decitabine for Injection Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Decitabine for Injection Sales Value Market Share by Country (2021-2026) Table 61. Global Decitabine for Injection Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Decitabine for Injection Sales Value Market Share by Country (2027-2032) Table 63. Astex Pharmaceuticals Company Information Table 64. Astex Pharmaceuticals Business Overview Table 65. Astex Pharmaceuticals Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Astex Pharmaceuticals Decitabine for Injection Product Portfolio Table 67. Astex Pharmaceuticals Recent Development Table 68. Hansoh Pharmaceutical Company Information Table 69. Hansoh Pharmaceutical Business Overview Table 70. Hansoh Pharmaceutical Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Hansoh Pharmaceutical Decitabine for Injection Product Portfolio Table 72. Hansoh Pharmaceutical Recent Development Table 73. Ingenus Pharmaceutical Company Information Table 74. Ingenus Pharmaceutical Business Overview Table 75. Ingenus Pharmaceutical Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Ingenus Pharmaceutical Decitabine for Injection Product Portfolio Table 77. Ingenus Pharmaceutical Recent Development Table 78. Meitheal Pharmaceuticals Company Information Table 79. Meitheal Pharmaceuticals Business Overview Table 80. Meitheal Pharmaceuticals Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Meitheal Pharmaceuticals Decitabine for Injection Product Portfolio Table 82. Meitheal Pharmaceuticals Recent Development Table 83. Otsuka US Company Information Table 84. Otsuka US Business Overview Table 85. Otsuka US Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Otsuka US Decitabine for Injection Product Portfolio Table 87. Otsuka US Recent Development Table 88. Sagent Pharmaceuticals Company Information Table 89. Sagent Pharmaceuticals Business Overview Table 90. Sagent Pharmaceuticals Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sagent Pharmaceuticals Decitabine for Injection Product Portfolio Table 92. Sagent Pharmaceuticals Recent Development Table 93. Huiyu Pharmaceutical Company Information Table 94. Huiyu Pharmaceutical Business Overview Table 95. Huiyu Pharmaceutical Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Huiyu Pharmaceutical Decitabine for Injection Product Portfolio Table 97. Huiyu Pharmaceutical Recent Development Table 98. Qilu Pharmaceutical Company Information Table 99. Qilu Pharmaceutical Business Overview Table 100. Qilu Pharmaceutical Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Qilu Pharmaceutical Decitabine for Injection Product Portfolio Table 102. Qilu Pharmaceutical Recent Development Table 103. Xian Janssen Pharmaceutical Company Information Table 104. Xian Janssen Pharmaceutical Business Overview Table 105. Xian Janssen Pharmaceutical Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Xian Janssen Pharmaceutical Decitabine for Injection Product Portfolio Table 107. Xian Janssen Pharmaceutical Recent Development Table 108. Chia Tai Tianqing Pharmaceutical Group Company Information Table 109. Chia Tai Tianqing Pharmaceutical Group Business Overview Table 110. Chia Tai Tianqing Pharmaceutical Group Decitabine for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Chia Tai Tianqing Pharmaceutical Group Decitabine for Injection Product Portfolio Table 112. Chia Tai Tianqing Pharmaceutical Group Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Decitabine for Injection Distributors List Table 116. Decitabine for Injection Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Decitabine for Injection Product Image Figure 2. Global Decitabine for Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Decitabine for Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Decitabine for Injection Sales (2021-2032) & (K Units) Figure 5. Global Decitabine for Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Decitabine for Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 50mg/Bottle Image Figure 10. Other Image Figure 11. Global Decitabine for Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Decitabine for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Decitabine for Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Decitabine for Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Decitabine for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Decitabine for Injection Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Decitabine for Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Decitabine for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Decitabine for Injection Sales Volume Share by Application (2021-2032) Figure 22. Global Decitabine for Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Decitabine for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Decitabine for Injection Sales Value Share by Application (2021-2032) Figure 25. Global Decitabine for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Decitabine for Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Decitabine for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Decitabine for Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Decitabine for Injection Sales Value (2021-2032) & (US$ Million) Figure 30. North America Decitabine for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Decitabine for Injection Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Decitabine for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Decitabine for Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Decitabine for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Decitabine for Injection Sales Value (2021-2032) & (US$ Million) Figure 36. South America Decitabine for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Decitabine for Injection Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Decitabine for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Decitabine for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Decitabine for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Decitabine for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Decitabine for Injection Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Decitabine for Injection Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg/Bottle
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Astex Pharmaceuticals
  • Hansoh Pharmaceutical
  • Ingenus Pharmaceutical
  • Meitheal Pharmaceuticals
  • Otsuka US
  • Sagent Pharmaceuticals
  • Huiyu Pharmaceutical
  • Qilu Pharmaceutical
  • Xian Janssen Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Decitabine for Injection Sales Value (2021-2032)
  4. 1.2.2 Global Decitabine for Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Decitabine for Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Decitabine for Injection Market Dynamics
  1. 2.1 Decitabine for Injection Industry Trends
  2. 2.2 Decitabine for Injection Industry Drivers
  3. 2.3 Decitabine for Injection Industry Opportunities and Challenges
  4. 2.4 Decitabine for Injection Industry Restraints
3 Decitabine for Injection Market by Company
  1. 3.1 Global Decitabine for Injection Company Revenue Ranking in 2025
  2. 3.2 Global Decitabine for Injection Revenue by Company (2021-2026)
  3. 3.3 Global Decitabine for Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Decitabine for Injection Average Price by Company (2021-2026)
  5. 3.5 Global Decitabine for Injection Company Ranking (2024-2026)
  6. 3.6 Global Decitabine for Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Decitabine for Injection Company Product Type and Application
  8. 3.8 Global Decitabine for Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Decitabine for Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Decitabine for Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Decitabine for Injection Market by Type
  1. 4.1 Decitabine for Injection Type Introduction
  2. 4.1.1 50mg/Bottle
  3. 4.1.2 Other
  4. 4.2 Global Decitabine for Injection Sales Volume by Type
  5. 4.2.1 Global Decitabine for Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Decitabine for Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Decitabine for Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Decitabine for Injection Sales Value by Type
  9. 4.3.1 Global Decitabine for Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Decitabine for Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Decitabine for Injection Sales Value Share by Type (2021-2032)
5 Decitabine for Injection Market by Application
  1. 5.1 Decitabine for Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Decitabine for Injection Sales Volume by Application
  5. 5.2.1 Global Decitabine for Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Decitabine for Injection Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Decitabine for Injection Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Decitabine for Injection Sales Value by Application
  9. 5.3.1 Global Decitabine for Injection Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Decitabine for Injection Sales Value by Application (2021-2032)
  11. 5.3.3 Global Decitabine for Injection Sales Value Share by Application (2021-2032)
6 Decitabine for Injection Regional Sales and Value Analysis
  1. 6.1 Global Decitabine for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Decitabine for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Decitabine for Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Decitabine for Injection Sales by Region (2027-2032)
  5. 6.3 Global Decitabine for Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Decitabine for Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Decitabine for Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Decitabine for Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Decitabine for Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Decitabine for Injection Sales Value (2021-2032)
  12. 6.6.2 North America Decitabine for Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Decitabine for Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Decitabine for Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Decitabine for Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Decitabine for Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Decitabine for Injection Sales Value (2021-2032)
  21. 6.9.2 South America Decitabine for Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Decitabine for Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Decitabine for Injection Sales Value Share by Country, 2025 VS 2032
7 Decitabine for Injection Country-level Sales and Value Analysis
  1. 7.1 Global Decitabine for Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Decitabine for Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Decitabine for Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Decitabine for Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Decitabine for Injection Sales by Country (2027-2032)
  6. 7.4 Global Decitabine for Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Decitabine for Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Decitabine for Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Decitabine for Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Decitabine for Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Decitabine for Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Decitabine for Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Decitabine for Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Decitabine for Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Decitabine for Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Decitabine for Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Decitabine for Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Decitabine for Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Decitabine for Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Decitabine for Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Decitabine for Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Decitabine for Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Decitabine for Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Decitabine for Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Decitabine for Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Decitabine for Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Decitabine for Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Decitabine for Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Decitabine for Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Decitabine for Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Decitabine for Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Decitabine for Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Decitabine for Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Decitabine for Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Decitabine for Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Decitabine for Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Decitabine for Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Decitabine for Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astex Pharmaceuticals
  2. 8.1.1 Astex Pharmaceuticals Company Information
  3. 8.1.2 Astex Pharmaceuticals Business Overview
  4. 8.1.3 Astex Pharmaceuticals Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Astex Pharmaceuticals Decitabine for Injection Product Portfolio
  6. 8.1.5 Astex Pharmaceuticals Recent Developments
  7. 8.2 Hansoh Pharmaceutical
  8. 8.2.1 Hansoh Pharmaceutical Company Information
  9. 8.2.2 Hansoh Pharmaceutical Business Overview
  10. 8.2.3 Hansoh Pharmaceutical Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Hansoh Pharmaceutical Decitabine for Injection Product Portfolio
  12. 8.2.5 Hansoh Pharmaceutical Recent Developments
  13. 8.3 Ingenus Pharmaceutical
  14. 8.3.1 Ingenus Pharmaceutical Company Information
  15. 8.3.2 Ingenus Pharmaceutical Business Overview
  16. 8.3.3 Ingenus Pharmaceutical Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ingenus Pharmaceutical Decitabine for Injection Product Portfolio
  18. 8.3.5 Ingenus Pharmaceutical Recent Developments
  19. 8.4 Meitheal Pharmaceuticals
  20. 8.4.1 Meitheal Pharmaceuticals Company Information
  21. 8.4.2 Meitheal Pharmaceuticals Business Overview
  22. 8.4.3 Meitheal Pharmaceuticals Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Meitheal Pharmaceuticals Decitabine for Injection Product Portfolio
  24. 8.4.5 Meitheal Pharmaceuticals Recent Developments
  25. 8.5 Otsuka US
  26. 8.5.1 Otsuka US Company Information
  27. 8.5.2 Otsuka US Business Overview
  28. 8.5.3 Otsuka US Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Otsuka US Decitabine for Injection Product Portfolio
  30. 8.5.5 Otsuka US Recent Developments
  31. 8.6 Sagent Pharmaceuticals
  32. 8.6.1 Sagent Pharmaceuticals Company Information
  33. 8.6.2 Sagent Pharmaceuticals Business Overview
  34. 8.6.3 Sagent Pharmaceuticals Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sagent Pharmaceuticals Decitabine for Injection Product Portfolio
  36. 8.6.5 Sagent Pharmaceuticals Recent Developments
  37. 8.7 Huiyu Pharmaceutical
  38. 8.7.1 Huiyu Pharmaceutical Company Information
  39. 8.7.2 Huiyu Pharmaceutical Business Overview
  40. 8.7.3 Huiyu Pharmaceutical Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Huiyu Pharmaceutical Decitabine for Injection Product Portfolio
  42. 8.7.5 Huiyu Pharmaceutical Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Decitabine for Injection Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Xian Janssen Pharmaceutical
  50. 8.9.1 Xian Janssen Pharmaceutical Company Information
  51. 8.9.2 Xian Janssen Pharmaceutical Business Overview
  52. 8.9.3 Xian Janssen Pharmaceutical Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Xian Janssen Pharmaceutical Decitabine for Injection Product Portfolio
  54. 8.9.5 Xian Janssen Pharmaceutical Recent Developments
  55. 8.10 Chia Tai Tianqing Pharmaceutical Group
  56. 8.10.1 Chia Tai Tianqing Pharmaceutical Group Company Information
  57. 8.10.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
  58. 8.10.3 Chia Tai Tianqing Pharmaceutical Group Decitabine for Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chia Tai Tianqing Pharmaceutical Group Decitabine for Injection Product Portfolio
  60. 8.10.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Decitabine for Injection Value Chain Analysis
  2. 9.1.1 Decitabine for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Decitabine for Injection Sales Mode & Process
  6. 9.2 Decitabine for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Decitabine for Injection Distributors
  9. 9.2.3 Decitabine for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst